161 related articles for article (PubMed ID: 23925696)
1. Puerperal mastitis: a reproductive event of importance affecting anti-mucin antibody levels and ovarian cancer risk.
Cramer DW; Williams K; Vitonis AF; Yamamoto HS; Stuebe A; Welch WR; Titus L; Fichorova RN
Cancer Causes Control; 2013 Nov; 24(11):1911-23. PubMed ID: 23925696
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms of MUC16 (CA125) and MUC1 (CA15.3) in relation to ovarian cancer risk and survival.
Williams KA; Terry KL; Tworoger SS; Vitonis AF; Titus LJ; Cramer DW
PLoS One; 2014; 9(2):e88334. PubMed ID: 24551091
[TBL] [Abstract][Full Text] [Related]
3. Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer.
Budiu RA; Mantia-Smaldone G; Elishaev E; Chu T; Thaller J; McCabe K; Lenzner D; Edwards RP; Vlad AM
Cancer Immunol Immunother; 2011 Jul; 60(7):975-84. PubMed ID: 21461842
[TBL] [Abstract][Full Text] [Related]
4. Anti-CA15.3 and Anti-CA125 Antibodies and Ovarian Cancer Risk: Results from the EPIC Cohort.
Cramer DW; Fichorova RN; Terry KL; Yamamoto H; Vitonis AF; Ardanaz E; Aune D; Boeing H; Brändstedt J; Boutron-Ruault MC; Chirlaque MD; Dorronsoro M; Dossus L; Duell EJ; Gram IT; Gunter M; Hansen L; Idahl A; Johnson T; Khaw KT; Krogh V; Kvaskoff M; Mattiello A; Matullo G; Merritt MA; Nodin B; Orfanos P; Onland-Moret NC; Palli D; Peppa E; Quirós JR; Sánchez-Perez MJ; Severi G; Tjønneland A; Travis RC; Trichopoulou A; Tumino R; Weiderpass E; Fortner RT; Kaaks R
Cancer Epidemiol Biomarkers Prev; 2018 Jul; 27(7):790-804. PubMed ID: 29661801
[No Abstract] [Full Text] [Related]
5. CA125 immune complexes in ovarian cancer patients with low CA125 concentrations.
Cramer DW; O'Rourke DJ; Vitonis AF; Matulonis UA; Dijohnson DA; Sluss PM; Crum CP; Liu BC
Clin Chem; 2010 Dec; 56(12):1889-92. PubMed ID: 20943848
[TBL] [Abstract][Full Text] [Related]
6. Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer.
Cramer DW; Titus-Ernstoff L; McKolanis JR; Welch WR; Vitonis AF; Berkowitz RS; Finn OJ
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1125-31. PubMed ID: 15894662
[TBL] [Abstract][Full Text] [Related]
7. Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort.
Fortner RT; Schock H; Le Cornet C; Hüsing A; Vitonis AF; Johnson TS; Fichorova RN; Fashemi T; Yamamoto HS; Tjønneland A; Hansen L; Overvad K; Boutron-Ruault MC; Kvaskoff M; Severi G; Boeing H; Trichopoulou A; Papatesta EM; La Vecchia C; Palli D; Sieri S; Tumino R; Sacerdote C; Mattiello A; Onland-Moret NC; Peeters PH; Bueno-de-Mesquita HBA; Weiderpass E; Quirós JR; Duell EJ; Sánchez MJ; Navarro C; Ardanaz E; Larrañaga N; Nodin B; Jirström K; Idahl A; Lundin E; Khaw KT; Travis RC; Gunter M; Johansson M; Dossus L; Merritt MA; Riboli E; Terry KL; Cramer DW; Kaaks R
Int J Cancer; 2018 Apr; 142(7):1355-1360. PubMed ID: 29159934
[TBL] [Abstract][Full Text] [Related]
8. Mumps and ovarian cancer: modern interpretation of an historic association.
Cramer DW; Vitonis AF; Pinheiro SP; McKolanis JR; Fichorova RN; Brown KE; Hatchette TF; Finn OJ
Cancer Causes Control; 2010 Aug; 21(8):1193-201. PubMed ID: 20559706
[TBL] [Abstract][Full Text] [Related]
9. Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer.
Terry KL; Titus-Ernstoff L; McKolanis JR; Welch WR; Finn OJ; Cramer DW
Cancer Epidemiol Biomarkers Prev; 2007 Jan; 16(1):30-5. PubMed ID: 17220329
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic potential of nanoparticle aided assays for MUC16 and MUC1 glycovariants in ovarian cancer.
Jain S; Nadeem N; Ulfenborg B; Mäkelä M; Ruma SA; Terävä J; Huhtinen K; Leivo J; Kristjansdottir B; Pettersson K; Sundfeldt K; Gidwani K
Int J Cancer; 2022 Oct; 151(7):1175-1184. PubMed ID: 35531590
[TBL] [Abstract][Full Text] [Related]
11. Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: antigens for multi-targeted antibody-guided therapy.
Chauhan SC; Vinayek N; Maher DM; Bell MC; Dunham KA; Koch MD; Lio Y; Jaggi M
J Histochem Cytochem; 2007 Aug; 55(8):867-75. PubMed ID: 17478446
[TBL] [Abstract][Full Text] [Related]
12. The use of mucin-specific monoclonal antibodies and lectins in the detection of tumor-associated serum markers in gynecological cancer.
Devine PL; McGuckin MA; Ramm LE; Harada H; Ward BG
Cancer Biochem Biophys; 1993 Sep; 13(4):221-38. PubMed ID: 8521372
[TBL] [Abstract][Full Text] [Related]
13. Anti-MUC1 antibodies and ovarian cancer risk: prospective data from the Nurses' Health Studies.
Pinheiro SP; Hankinson SE; Tworoger SS; Rosner BA; McKolanis JR; Finn OJ; Cramer DW
Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1595-601. PubMed ID: 20501761
[TBL] [Abstract][Full Text] [Related]
14. Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women.
Richards ER; Devine PL; Quin RJ; Fontenot JD; Ward BG; McGuckin MA
Cancer Immunol Immunother; 1998 Jul; 46(5):245-52. PubMed ID: 9690452
[TBL] [Abstract][Full Text] [Related]
15. Spectrally separated dual-label upconversion luminescence lateral flow assay for cancer-specific STn-glycosylation in CA125 and CA15-3.
Ekman M; Salminen T; Raiko K; Soukka T; Gidwani K; Martiskainen I
Anal Bioanal Chem; 2024 May; 416(13):3251-3260. PubMed ID: 38584178
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with a mixed vaccine of autogenous and allogeneic breast cancer cells and tumor associated antigens CA15-3, CEA and CA125--results in immune and clinical responses in breast cancer patients.
Jiang XP; Yang DC; Elliott RL; Head JF
Cancer Biother Radiopharm; 2000 Oct; 15(5):495-505. PubMed ID: 11155821
[TBL] [Abstract][Full Text] [Related]
17. Identification of Anti-CA125 Antibody Responses in Ovarian Cancer Patients by a Novel Deep Sequence-Coupled Biopanning Platform.
Frietze KM; Roden RB; Lee JH; Shi Y; Peabody DS; Chackerian B
Cancer Immunol Res; 2016 Feb; 4(2):157-64. PubMed ID: 26589767
[TBL] [Abstract][Full Text] [Related]
18. Correlates of the preoperative level of CA125 at presentation of ovarian cancer.
Cramer DW; Vitonis AF; Welch WR; Terry KL; Goodman A; Rueda BR; Berkowitz RS
Gynecol Oncol; 2010 Dec; 119(3):462-8. PubMed ID: 20850174
[TBL] [Abstract][Full Text] [Related]
19. A biosensor for determination of the circulating biomarker CA125/MUC16 by Surface Plasmon Resonance Imaging.
Szymańska B; Lukaszewski Z; Hermanowicz-Szamatowicz K; Gorodkiewicz E
Talanta; 2020 Jan; 206():120187. PubMed ID: 31514860
[TBL] [Abstract][Full Text] [Related]
20. Detection of glyco-mucin profiles improves specificity of MUC16 and MUC1 biomarkers in ovarian serous tumours.
Ricardo S; Marcos-Silva L; Pereira D; Pinto R; Almeida R; Söderberg O; Mandel U; Clausen H; Felix A; Lunet N; David L
Mol Oncol; 2015 Feb; 9(2):503-12. PubMed ID: 25454345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
